Navigation Links
Spring Bioscience launches highly sensitive PD-L1 (SP142) antibody, a component of Roche's immunotherapy assay

PLEASANTON, Calif., Aug. 25, 2014 /PRNewswire/ -- Spring Bioscience (Spring), a member of the Roche Group, today announced the launch of its PD-L1 (SP142) rabbit monoclonal immunohistochemistry (IHC) antibody1. This new PD-L1 clone was developed for Roche/Genentech's anti-PD-L1 (MPDL3280A) immunotherapy development program. The SP142 antibody is a component of the clinical trial assay designed by Ventana Medical Systems, Inc. (Ventana), and used in early and late stage clinical trials for various tumor types including non-small cell lung cancer (NSCLC) and urothelial bladder cancer (UBC).

As pharmaceutical companies continue to research and develop cancer drugs that target the immune system, measuring the amount of PD-L1 protein expressed on tumor cells and tumor-infiltrating immune cells may help assess the efficacy and durability of investigational drugs that inhibit the binding of the PD-L1 protein.

Internal comparison studies performed at Spring demonstrated that the PD-L1 (SP142) antibody outperformed other commercially available PD-L1 antibodies. "As with all IHC antibodies developed by Spring, the SP142 antibody will deliver the high quality and accuracy that clinical researchers need to confidently assess PD-L1 status in tissue samples," said Michael Rivers, GM, Spring Biosience. 

"The development of the PD-L1 (SP142) antibody, with its high degree of sensitivity and specificity, may make this a key component of a future companion diagnostic IHC test for Roche's investigational anti-PD-L1 therapy. As researchers strive to understand the clinical relevance of PD-L1 expression, this clone may offer a superior ability to stain and analyze both tumor and immune cells," said Doug Ward, VP and Lifecycle Leader, Ventana Compaion Diagnostics. "Ventana and Spring are committed to delivering gold standard biomarker detection solutions for companion diagnostic tests."

Spring Bioscience is known across the research industry for its quality development practices and for delivering a consistent supply of highly-specific antibodies. SP142 meets the company's high standards as a valuable tool for assessing PD-L1 expression in many different tumor types.

Recommended staining protocols are available for manual, semi-automated and VENTANA Discovery platforms for decreased assay development times.

To order or request additional information on SP142, please visit or call (800) 787-6896 or (925) 474-8440. Orders can also be submitted via e-mail at with technical detail available through

1PD-L1 (SP142) Rabbit Monoclonal Antibody is for Research Use Only (RUO). Not for use in diagnostic procedures.

About Spring Bioscience
Spring Bioscience, Inc. (Spring) is a leading developer of rabbit monoclonal antibodies, engineered for immunohistochemistry (IHC) and other applications in tissue-based cancer research. Founded by scientists with a primary focus on IHC, Spring has developed a proprietary menu of highly-sensitive antibodies (SP clones) that yield superior specificity and consistency in research and clinical practice. Spring is committed to high-quality development standards and also offers a portfolio of advanced detection and other complementary products for reliable, reproducible assessments of protein expression. Spring Bioscience was acquired by Ventana Medical Systems, Inc., a member of the Roche Group, in 2007. As an antibody center of excellence for Roche with strong pharmaceutical partnerships across the industry, Spring is at the frontier of antibody development for companion diagnostics, IVD and early clinical markers. Learn more at

About Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA products are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to help reduce errors, support diagnosis and enable informed treatment decisions by anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies.

VENTANA, the VENTANA logo, and DISCOVERY are trademarks of Roche.

VMSI Media Relations
Jacqueline Bucher
Senior Director, Corporate Communications
Ventana Medical Systems, Inc.
Tel 520.877.7288 o
Tel 520.468.9145 m
e-mail: Jacquie Bucher

Photo -

SOURCE Spring Bioscience
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
2. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
3. Neusoft Medical Launches NeuViz 64 Multi-slice CT Scanner at CMEF Spring 2012
4. Islet Sciences Announces Strategic Alliance with Spring Point Project
5. Spring Bank Pharmaceuticals Closes $10.5 million Series A Financing to fund Phase I Clinical Trials in HCV-infected Patients
6. SI-BONE, Inc. Announces Spring Society Meeting Attendance
7. Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
8. GlySure CEO to Present ICU Trial Results at Spring Medtech Industry Conferences
9. Spring Allergies Start Strong and Last Long As Extreme Weather Patterns Continue
10. Hurel Receives $9.2 Million Series A Funding From Spring Mountain Capital
11. Neusoft Medical Launches New Products to Global Market at 2013 Spring CMEF
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... potential to use SyMRI to find optimal contrast weighting of ... tumor metastases, and has signed a research agreement with SyntheticMR ... the hospital. Using SyMRI, it is possible to generate multiple ... settings after the patient has left, thus making it possible ...
(Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
Breaking Medicine Technology:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... On November ... training center for the Narconon network, announced the release of a new cutting edge ... the Narconon organization has been working with drug- and alcohol-addicted individuals with the purpose ...
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 23rd ... Tri Lite’s personal heating products business. Cozy Products explains what this means ... that fit in well with the Cozy Products business model: to sell personal heaters ...
(Date:11/25/2015)... ALTO, Calif. (PRWEB) , ... November 25, 2015 , ... ... Smart and Beddit Classic sleep tracking systems. The new app features a more intuitive ... see and understand how well you slept. The SleepScore is created by a proprietary ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I saw a ... “I thought there had to be a convenient and comfortable way to protect them ... enables disabled individuals to safely travel during cold or inclement weather. In doing so, ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
Breaking Medicine News(10 mins):